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Abstract
Introduction: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality due to cardiovascular
disease, and this occurs early in the disease process. The metabolic syndrome (MetS) may contribute to the excess
cardiovascular burden observed in RA; however, little information is available regarding MetS in early RA. We aimed
to identify the prevalence of MetS and to determine the potential factors associated with the presence of MetS in
Vietnamese women with early RA.
Methods: A total of 105 consecutive women with early RA (disease duration ≤3 years) and 105 age-matched
healthy women were checked for MetS according to six MetS definitions (Joint Consensus, International Diabetes
Federation, National Cholesterol Education Program 2004 and 2001, European Group for Study of Insulin Resistance,
and World Health Organization). Multivariate logistic regression models were constructed to determine
independent predictors of MetS in women with RA.
Results: Prevalence of MetS varied from 16.2% to 40.9% according to the definitions used in women with RA, and was
higher (P < 0.001) than in healthy controls (from 10.5% to 22.9%). Among individual components of MetS, differences
between women with RA and controls were observed for hypertension (P < 0.001), low high density lipoprotein-
cholesterol (HDL-C) levels (P < 0.001), and abdominal obesity (P = 0.019). After adjusting for age and physical activity,
higher erythrocyte sedimentation rate (ESR) (odds ratios (OR) = 1.516, 95% confidence interval (CI): 1.073 to 3.195,
P = 0.042), disease activity score (DAS28) (OR = 1.736, 95% CI: 1.293 to 2.786, P = 0.019), health assessment questionnaire
(HAQ) score (OR = 1.583, 95% CI: 1.195 to 2.367, P = 0.035), and less methotrexate use (OR = 0.736, 95% CI: 0.547 to
0.962, P = 0.024) remained significant independent predictors of the presence of MetS in women with RA.
Conclusions: Women with early RA already had higher prevalence of MetS compared with healthy controls.
Higher systemic inflammatory marker, disease activity and disability scores, and less methotrexate use were
independent predictors associated with the presence of MetS in women with early RA. These findings suggest that
physicians should screen for MetS in women with early RA to control its components and therefore reduce their
risk of cardiovascular diseases.
Introduction
Rheumatoid arthritis (RA), the most common chronic
inflammatory arthritis in women, is associated with
increased morbidity and mortality [1] due to cardiovas-
cular disease (CVD) [2], mostly accelerated atherosclero-
tic CVD [3,4]. Therefore, European League Against
Rheumatism (EULAR) guidelines recommend that cardi-
ovascular risk screening and management strategies are
urgently needed in patients with RA [5]. Such strategies
are generally done on the basis of a cardiovascular risk
score calculator, such as the Framingham score (often
used in the United States) [6] and the Systemic Coron-
ary Risk Evaluation (SCORE) model (often used in
Europe) [7]. In these models, traditional cardiovascular
risk factors such as age, gender, smoking status, blood
pressure (BP), cholesterol and high-density lipoprotein
cholesterol (HDL-C) levels are integrated [5-8]. Risk
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population, however, little information regarding these
models is available in RA populations [5,8].
Although traditional cardiovascular risk factors such
as hypertension [2,9], central obesity [10,11], dyslipidae-
mia [12,13], and insulin resistance [14-16] may occur
more frequently among patients with RA, this does not
fully account for the rates of CVD observed [17], novel
risk factors, particularly systemic inflammation, have
also been implicated [18].
Metabolic syndrome (MetS), also known as syndrome
X and insulin resistance syndrome, is a cluster of classi-
cal cardiovascular risk factors including insulin resis-
tance, central obesity, hypertension, high triglycerides
(TG) levels and low HDL levels [19]. MetS has been
identified as an independent cardiovascular risk factor,
conferring risk beyond the sum of its individual compo-
nents [20]. MetS increases the risk for atherosclerotic
CVD up to three times, and for type 2 diabetes mellitus
up to five times [21]. Furthermore, MetS also increases
mortality from CVD and all-causes in the general popu-
lation [22]. At present, six definitions for MetS have
been established: the Joint Consensus 2009 of the Inter-
national Diabetes Federation (IDF) Task Force, National
Heart, Lung, and Blood Institute, American Heart Asso-
ciation, World Heart Federation, International Athero-
sclerosis Society, and International Association for the
Study of Obesity [23], the IDF 2005 [24], the National
Cholesterol Education Program (NCEP) 2004 [21] and
2001 [25], the European Group for Study of Insulin
Resistance (EGIR) 1999 [26], and the World Health
Organization (WHO) 1998 [27]. These definitions have
many similarities; however, they differ in some of the
components, as well as in their specified cut-offs and
weighting. In the general population, the prevalence of
MetS has been shown to vary considerably according to
the definition used, with the IDF criteria tending to
report the highest and the EGIR criteria the lowest [23].
In patients with RA to date, eight other studies [28-35]
and two reviews [36,37] have commented on the preva-
lence of MetS, reporting prevalence rates ranging from
12.1 to 45.3%, but most of the studies have been con-
ducted in the long-standing disease (9.5 to 24 years).
There is evidence that CVD morbidity and mortality
occur early in the disease process [38,39]. Increased
carotid intima media thickness [40-42], endothelial
dysfunction [43,44], dyslipidaemia [45,46], and the
pathogenic process for atherosclerosis may be in place
even before a diagnosis of RA [43]. However, little infor-
mation is available regarding MetS in early RA. Only
one study [31] has investigated MetS in American
patients with early RA (disease duration ≤3 years) and
reported that the prevalence of the MetS was signifi-
cantly greater in RA patients compared to controls.
There is evidence that under a given body mass index
(BMI), body fat percentage is greater in Asians than
Caucasians [47], and greater in RA patients than con-
trols [48]. Therefore, Asian RA patients may be predis-
posed to more unfavourable cardiometabolic risk;
however, there is no available information in the litera-
ture regarding MetS in this population.
During the last two decades, the socio-economic condi-
tion and lifestyle have profoundly changed in Vietnam; and
these changes had strong effects on disease patterns in the
population [49]. The prevalence of non-communicable dis-
eases such as obesity, hypertension, and diabetes has been
rapidly increasing; and the relationship among urbaniza-
tion, sedentary lifestyle and these diseases was also demon-
strated [49]. The mean BMI of Vietnamese increased from
19 to 23 kg/m
2; and the prevalence of MetS recently
reached 12% in the general population [50]. However,
MetS has not yet been studied among patients with RA in
Vietnam. Therefore, the present study was designed to (1)
identify the prevalence of MetS according to all definitions
currently used, in order to compare between other studies
and (2) determine the potential factors associated with the
presence of MetS in Vietnamese women with early RA.
Materials and methods
Study design and subjects
This study was designed as a cross-sectional investigation
with two comparison groups. The first comprised 105
consecutive Vietnamese women with RA, from 26 to
73 years, who visited our Outpatient Department from
October 2007 to March 2009. The second group was
made up of 105 age-matched (± 2 years) healthy women
who were selected randomly from applicants for an
annual health check. They were judged normal on physi-
cal examination. All patients fulfilled the American Col-
lege of Rheumatology (ACR) 1987 classification criteria
for RA [51], with disease duration ≤3 years. Written
informed consent based on the Helsinki Declaration was
obtained from each subject. The study was approved by
the Research and Ethical Review Board of the Bach Mai
University Hospital, Hanoi, Vietnam.
Assessments
Interviews were performed with a questionnaire identify-
ing risk factors for MetS, such as lifestyle, age, smoking,
menopausal status, disease duration and RA medica-
tions. A family history of coronary-artery disease was
defined as a first-degree relative having had a myocar-
dial infarction or stroke before age 55 in males and 65
in females [31]. Physical activity was defined by the
seven-day physical activity recall questionnaire [52]. The
assessments include a clinical examination, comprising
swollen joint count (28 joints) and tender joint count
(28 joints). Patients were also evaluated in terms of
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score (DAS28) (using erythrocyte sedimentation rate
(ESR) [53] and the Health Assessment Questionnaire
(HAQ) [54], respectively. Pain and general health were
measured by a visual analogue scale (VAS).
Height and weight were measured and BMI was calcu-
lated as body weight divided by the square of the height
(kg/m²). In accordance with WHO standards, for Asian
populations, individuals with a BMI <18.5 kg/m² are
considered underweight, between 18.5 to 22.9 as normal,
23 to 27.49 as overweight and values greater than 27.5
indicate obesity [55]. Waist circumference (WC) was
measured with an inelastic tape, placed directly on the
skin, perpendicularly to the long axis of the body while
the subject stood balanced on both feet, with both arms
hanging freely. The measurement was taken at the end
of expiration, at the midway between the costal arch
and the iliac crest to the nearest 0.1 cm. BP was mea-
sured by a mercury sphygmomanometer in the sitting
position after five minutes of rest.
Biological tests were performed from venous blood
samples obtained the morning after an overnight fast.
Plasma fasting glucose (FG) levels were measured using
the glucose oxydase method. HDL-C and low-density
lipoprotein cholesterol (LDL-C) levels were measured
using corresponding non-precipitating method. Serum
creatinine, TG, and total cholesterol (TC) were measured
by an auto-analyser (Olympus AU 400, Olympus, Tokyo,
Japan). A renal function assessment was performed by
estimation of glomerular filtration rate according to the
Modification of Diet in Renal Disease (MDRD) equation.
For women with RA, rheumatoid factor (RF) and ESR
were additionally measured. IgM-RF was assessed by
enzyme-linked immunosorbent assay (ELISA), with sero-
positivity defined as ≥40 units.
The estimated cardiovascular risk of fatal CVD within
10 years was calculated using the SCORE model [7],
according to the EULAR recommendations for cardio-
vascular risk management in patients with RA and other
forms of inflammatory arthritis [5]. A cut-off point of
SCORE >10% was used to define the subjects at high
risk cardiovascular [5,7].
MetS was assessed according to all existing definitions
(Joint Consensus [23], IDF [24], NCEP 2004 [21] and
2001 [25], EGIR [26], and WHO [27]). Details of these
criteria are presented in Table 1.
Statistical analyses
Data were presented as mean and 95% confidence inter-
val (CI) for normally distributed continuous variables as
well as median and inter-quartile range for skewed con-
tinuous variables. Frequency and percentage were used
for categorical variables. Comparisons of the values
between women with RA and controls were performed
using the paired t-test for continuous variables and the
chi-square test for categorical variables. Multivariate
logistic regression models were constructed and odds
ratios (OR) and 95% CI were calculated to investigate
the independent of the predictors of individual
RA-related characteristics and MetS in women with
RA. All statistical analyses were done using the SPSS
version 17.0 for Windows (SPSS Inc, Chicago, IL,
USA). Statistical significance was defined as the two-
tailed P-value < 0.05.
Results
Descriptive characteristics of study population
The median age was 56.3 and 55.7 years in women with
RA and healthy controls, respectively. Women with RA
had median disease duration of 21 months, and moderate
disease activity (mean DAS28 score 4.1). The proportion
of patients with low (DAS28 score <3.2), moderate
(DAS28 score 3.2 to 5.1) and high (DAS28 score >5.1)
disease activity were 36.2%, 52.5%, and 11.3%, respec-
tively. The majority of patients with RA were currently
treated with disease-modifying anti-rheumatic drugs
(DMARDs) (89.5%), and glucocorticoids (68.6%) with
mean daily dose of 8.6 ± 3.7 mg. Because biologic
DMARDs have not yet been available in Vietnam, thus
none of the patients with RA was treated with those
drugs. There were no smokers among the participants.
Demographic and anthropometric characteristics of
women with RA and healthy controls are presented in
Table 2. No significant differences were seen between the
two groups according to the proportion of postmenopau-
sal female and family history of coronary disease. Com-
pared with the healthy controls, women with RA had
lower physical activity (P < 0.001). Although means of
weight and BMI were similar between the two groups,
the proportion of women with RA in the normal weight
category was lower (P = 0.006), and in the overweight
category was higher (P = 0.047) compared with healthy
controls. WC was higher in women with RA compared
with healthy controls (P = 0.007). Systolic BP was higher
(P = 0.017) in women with RA while diastolic BP was
similar between the two groups.
Biological characteristics of study population
Means of total cholesterol and triglycerides levels were
not significantly different between the two groups. As
expected, HDL-C levels were lower (P = 0.018), and
TC/HDL-C ratio and LDL-C were higher (P =0 . 0 3a n d
0.046, respectively) in women with RA compared with
healthy controls. No significant differences were seen
between the two groups according to glycaemia, creati-
nine, and creatinine clearance (Table 3).
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the SCORE model
The SCORE function was higher (P < 0.001) and the
proportion of high risk (SCORE >10%) in RA patients
was almost doubled (15.3% vs 8.6%, P <0 . 0 0 1 )c o m -
pared to those in healthy controls (Table 3).
Prevalence of the metabolic syndrome in study
population according to definition used
There was great diversity in the reported prevalence
rates according to the definition used (Table 4). Preva-
lence of MetS in women with RA ranged from 16.2% to
40.9%, with EGIR reporting the lowest rate, the IDF
reporting the highest rate, and the most updated Joint
Consensus 2009 criteria and most commonly used
NCEP 2004 reporting a rate of 32.4%. The prevalence
rates were higher (P < 0.001) than that in healthy con-
trols (ranging from 10.5% to 22.9%), and almost doubled
in the young and middle-aged groups, irrespective of the
criteria used. The prevalence increased with age (P <
0.001) in both groups (Table 4). Differences among
women with RA and healthy controls were present for
hypertension (P < 0.001), low HDL-C levels (P < 0.001),
and abdominal obesity (P = 0.019). Among individual
components of MetS, the most prevalent were low
HDL-C levels, abdominal obesity, and hypertension in
women with RA; and abdominal obesity, high TG levels,
and hypertension in healthy controls (Tables 2 and 3).
Table 1 A summary of the definitions of the metabolic syndrome
JC 2009 IDF 2005 NCEP 2004 NCEP 2001 EGIR 1999 WHO 1998
Number of
criteria
Three or more of: And two or more
of:
Three or more of: Three or more of: And two or
more of:
And two or more
of:
Obesity Population and country -
specific definition
WC ≥ 94 (men)
WC ≥ 80 (women)*
WC ≥ 102 (men)
WC ≥ 88 (women)
WC ≥ 102 (men)
WC ≥ 88 (women)
WC ≥ 94
(men)
WC ≥ 80
(women)
BMI >30 and/or
WHR >0.9 (men)
WHR >0.85
(women)
Hypertension
(mmHg)
≥ 130/85** ≥ 130/85** ≥ 130/85** ≥ 130/85** ≥ 140/90** ≥ 140/90
HDL-C (mmol/l) < 1.0 (men) <1.3 (women)** < 1.0 (men) <1.3
(women)**
< 1.0 (men) <1.3
(women)**
< 1.0 (men) <1.3
(women)**
<1.0** < 0.9 (men) <1.0
(women)**
TG (mmol/l) ≥1.7** >1.7** ≥1.7** ≥1.7** >2.0** ≥1.7**
Glucose (mmol/l) ≥5.6** ≥5.6** ≥5.6** ≥6.1** ≥6.1, insulin in
top 25%
≥6.1, DM, IGT, IR
Albumin/
creatinine (mg/l)
N/A N/A N/A N/A N/A ≥30
Text in italics: prerequisite for diagnosis, in addition to the number of other criteria needed to be met. * cut-off values differ according to ethnic origin, ** or
treated for abnormality. BMI: body mass index; DM, diabetes mellitus; EGIR, European Group for Study of Insulin Resistance; HDL-C, high-density lipoprotein-
cholesterol; IDF, International Diabetes Federation; IGT, impaired glucose tolerance; IR, insulin resistance; JC, Joint Consensus; N/A, not applicable; NCEP/ATP,
National Cholesterol Education Program Adult Treatment Panel; TG, triglycerides; WC, waist circumference; WHO, World Health Organization; WHR, waist hip ratio.
Table 2 Demographic and anthropometric characteristics of women with RA and healthy controls
Variables RA patients (n = 105) Controls (n = 105) P-value
Age, median (range), years 56.3 (26 to 73) 55.7 (25 to 72) 0.583
Postmenopausal female, n (%) 52 (49.5) 49 (46.7) 0.394
Family history of coronary disease, n (%) 22 (20.9) 23 (21.9) 0.138
Regular intentional exercise, n (%) 26 (24.8) 43 (40.9) <0.001
Body weight, kg 54.7 (53.3 to 56.1) 53.4 (51.9 to 54.8) 0.369
Body mass index (BMI), kg/m
2 23.1 (22.4 to 23.8) 22.5 (21.9 to 23.2) 0.473
Underweight (BMI <18.5), n (%) 12 (11.4) 9 (8.6) 0.296
Normal weight (BMI: 18.5 to 22.9), n (%) 41 (39.1) 52 (49.5) 0.006
Overweight (BMI: 23 to 27.49), n (%) 37 (35.2) 31 (29.5) 0.047
Obese (BMI ≥27.5), n (%) 15 (14.3) 13 (12.4) 0.317
Waist circumference, cm 85.3 (83.8 to 86.8) 78.5 (77.2 to 79.8) 0.007
Waist circumference ≥88, n (%) 16 (15.2) 9 (8.6) 0.005
Waist circumference ≥80, n (%) 49 (46.7) 32 (30.5) 0.019
Systolic blood pressure, mmHg 128.3 (126.1 to 130.5) 117.6 (115.5 to 119.7) 0.017
Diastolic blood pressure, mmHg 79.1 (77.9 to 80.3) 73.4 (72.3 to 74.5) 0.343
Blood pressure ≥130/85 mmHg, n (%) 39 (37.1) 27 (25.7) <0.001
Values are the mean (95% CI) unless otherwise indicated.
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(P < 0.05) than prevalence of MetS, irrespective of the
criteria used in the both women with RA and healthy
controls (Tables 3 and 4).
Associations of the metabolic syndrome in women
with RA
Characteristics of women with RA who had and who
did not have MetS are presented in Table 5. Results pre-
sented were only for the NCEP 2004 criteria, but were
very similar when we used other criteria, despite the dif-
ference in prevalence.
In univariate analysis, women with RA with the MetS
were older (P = 0.003), had less regular intentional exer-
cise (P < 0.001), longer disease duration (P = 0.046),
higher RF positivity (P = 0.049), higher ESR (P =0 . 0 3 8 ) ,
higher DAS28 score (P = 0.007), higher HAQ score (P =
0.043), higher SCORE function (P < 0.001), higher
proportion of SCORE >10% (P < 0.001), higher anti-
hypertensive and statin/fibrate use (P < 0.001), and less
methotrexate use (P < 0.001), compared with those who
did not have the MetS. Sulphasalazine, hydroxychloro-
quine, glucocorticoids and NSAIDs/COX-II use were
not significantly associated with the presence of the
MetS. The independence of each of these associations
was tested in a multivariate logistic regression model.
After adjusting for age and physical activity, higher ESR
(OR = 1.516, 95% CI: 1.073 to 3.195, P = 0.042), higher
DAS28 score (OR = 1.736, 95% CI: 1.293 to 2.786, P =
0.019), higher HAQ score (OR = 1.583, 95% CI: 1.195 to
Table 3 Biological characteristics and SCORE of women with RA and healthy controls
Variables RA patients (n = 105) Controls (n = 105) P-value
Total cholesterol, mmol/l 5.3 (5.2 to 5.4) 5.2 (5.1 to 5.3) 0.296
Total cholesterol ≥5.2, n (%) 52 (49.5) 50 (47.6) 0.413
HDL-cholesterol, mmol/l 1.33 (1.29 to 1.37) 1.68 (1.62 to 1.74) 0.018
HDL-cholesterol ≤1.29, n (%) 53 (50.5) 24 (22.9) <0.001
Total cholesterol/HDL to C ratio 3.98 (3.77 to 4.19) 3.09 (2.86 to 3.32) 0.037
LDL-cholesterol, mmol/l 3.1 (2.9 to 3.2) 2.6 (2.5 to 2.7) 0.046
LDL-cholesterol ≥2.6, n (%) 49 (46.7) 48 (45.7) 0.161
Triglycerides, mmol/l 2.07 (2.04 to 2.11) 1.96 (1.94 to 1.98) 0.134
Triglycerides ≥1.69, n (%) 33 (31.4) 31 (29.5) 0.193
Glycemia, mmol/l 5.4 (5.3 to 5.5) 5.3 (5.2 to 5.4) 0.177
Glycemia ≥6.1, n (%) 10 (9.5) 9 (8.6) 0.219
Glycemia ≥5.6, n (%) 17 (16.2) 15 (14.3) 0.167
Creatinine, mmol/l 69.2 (67.9 to 70.4) 68.7 (67.5 to 69.9) 0.574
Creatinine clearance (ml/min) 80.8 (78.6 to 83.1) 81.6 (79.4 to 83.8) 0.358
SCORE function, %, mean (S.D.) 8.9 (3.6) 5.8 (2.7) <0.001
SCORE >10%, n (%) 16 (15.3) 9 (8.6) <0.001
Values are the mean (95% CI) unless otherwise indicated. HDL, high-density lipoprotein; LDL, low-density lipoprotein. RA, rheumatoid arthritis; SCORE, Systemic
Coronary Risk Evaluation.
Table 4 Prevalence of metabolic syndrome according to different criteria used
n JC 2009 IDF 2005 NCEP 2004 NCEP 2001 EGIR 1999 WHO 1998
Total
RA 105 34 (32.4)†‡ 43 (40.9)†‡ 34 (32.4)†‡ 26 (24.7)†‡ 17 (16.2)†‡ 20 (19.0)†‡
Controls 105 19 (18.1) 24 (22.9) 19 (18.1) 15 (14.2) 11 (10.5) 13 (12.4)
20 to 39 years
RA 19 5 (26.3)† 7 (36.8)† 5 (26.3)† 2 (10.6)† 1 (5.3)† 1 (5.3)†
Controls 19 2 (10.6) 3 (15.8) 2 (10.6) 1 (5.3) 0 (0) 0 (0)
40 to 59 years
RA 51 16 (31.4)† 21 (41.2)† 16 (31.4)† 13 (25.5)† 8 (15.7)† 10 (19.6)†
Controls 51 8 (15.7) 10 (19.6) 8 (15.7) 7 (13.7) 5 (9.8) 6 (11.8)
≥60 years
RA 35 13 (37.1)† 17 (48.6)† 13 (37.1)† 11 (31.4)† 8 (22.9)† 9 (25.7)†
Controls 35 9 (25.7) 11 (31.4) 9 (25.7) 7 (20.0) 6 (17.1) 7 (20.0)
Values are the number (%); EGIR, European Group for Study of Insulin Resistance; IDF, International Diabetes Federation; JC, Joint Consensus; NCEP/ATP, National
Cholesterol Education Program Adult Treatment Panel; RA, rheumatoid arthritis; WHO, World Health Organization. †: p < 0.001 for comparison between RA
patients and healthy controls; ‡: p < 0.001 for comparison between different age groups in RA patients and healthy controls.
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0.736, 95% CI: 0.547 to 0.962, P = 0.024) remained sig-
nificant independent predictor of the presence of the
MetS in women with RA (Table 6).
Discussion
This study was carried out in Vietnamese women with
early RA and found that: 1. Prevalence of the MetS was
significantly higher, almost doubled in the young and
middle-aged groups, in women with RA compared with
healthy controls, irrespective of the criteria used. 2. In
women with RA, higher systemic inflammatory markers,
or disease activity and disability scores, and less
methotrexate use were independent predictors asso-
ciated with the presence of the MetS, independently to
age and physical activity.
To our knowledge, this is the first study to investigate
the prevalence of MetS using all definitions in Asian
patients with RA, and the second study in early RA in
the literature [31]. Although most experts recognize that
obesity-related insulin resistance may be the fundamen-
tal cause of MetS, each society has its emphasis in defin-
ing the syndrome. The WHO criteria [27] and the EGIR
criteria [26] centre on diabetes and insulin resistance,
whereas the IDF [24] focuses on central obesity as the
essential condition, while the NCEP guidelines [21,25]
give equal weight to each component of MetS like Joint
Consensus 2009 [23]. Furthermore, cut-off points of
individual components of MetS, particularly for WC, are
different between the definitions (Table 1). This may
explain a great diversity in the prevalence of MetS
according to the definitions used, with EGIR reporting
the lowest rate, the IDF criteria reporting the highest
rate as shown in ours and an earlier study [32]. We
used all MetS definitions currently used in order to
compare our results to those of previous studies in
patients with RA [28-35] and in the Vietnamese popula-
tion [50]. The prevalence of MetS in women with early
RA in our study was significantly higher than that in
Table 5 Characteristics of women with RA according to the presence or absence of metabolic syndrome
Variables Total (n = 105) With MetS
(n = 34)
Without MetS
(n = 71)
P-value
Demographics
Age, median (range), years 52.7 (26 to 71) 54.6 (26 to 71) 50.8 (26 to 71) 0.003
Postmenopausal women, n (%) 52 (49.5) 16 (47.1) 36 (50.7) 0.271
Regular intentional exercise, n (%) 26 (24.8) 5 (14.3) 21 (29.6) <0.001
Family history of CHD, n (%) 22 (20.9) 7 (20.6) 15 (21.1) 0.537
RA disease characteristics
RA duration, median (range), months 21 (3 to 36) 26 (3 to 36) 16 (3 to 36) 0.046
RF seropositivity, n (%) 73 (69.5) 25 (73.5) 48 (67.6) 0.049
ESR (mm in first hour), mean (S.D.) 27.5 (13.9) 33.6 (11.3) 21.4 (9.6) 0.038
DAS28 score, mean (S.D.) 4.1 (1.3) 4.7 (1.5) 3.5 (1.1) 0.007
HAQ score (range 0 to 3), mean (S.D.) 0.96 (0.57) 1.13 (0.58) 0.79 (0.55) 0.043
SCORE function, %, mean (S.D.) 8.9 (3.6) 9.7 (4.2) 8.1 (3.1) <0.001
SCORE >10%, n (%) 16 (15.3) 8 (23.6) 9 (12.6) <0.001
Current RA medications
Methotrexate, n (%) 68 (64.8) 18 (52.9) 50 (70.4) <0.001
Sulphasalazine, n (%) 32 (30.5) 10 (29.4) 22 (30.9) 0.714
Hydroxychloroquine, n (%) 64 (60.9) 21 (61.7) 43 (60.5) 0.113
NSAIDs/COX-II, n (%) 29 (27.6) 10 (29.4) 19 (26.8) 0.139
Glucocorticoids use, n (%) 72 (68.6) 23 (67.6) 49 (69.1) 0.162
Anti-hypertensive, n (%) 20 (19.1) 9 (26.5) 11 (15.5) <0.001
Statin/fibrate, n (%) 19 (18.1) 11 (32.3) 8 (11.3) <0.001
CHD, coronary heart disease; COX-II, cyclooxygenase II inhibitor; DAS28, 28-joint disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health
Assessment Questionnaire; MetS, metabolic syndrome; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; SCORE,
Systemic Coronary Risk Evaluation.
Table 6 Odds ratios for having the metabolic syndrome
in women with RA*
Factors Odds ratios (95% CI) P-value
Disease duration 1.163 (0.971 to 1.924) 0.372
Rheumatoid factor seropositivity 1.092 (0.973 to 1.358) 0.547
ESR 1.516 (1.073 to 3.195) 0.042
DAS28 score 1.736 (1.293 to 2.786) 0.019
HAQ score 1.583 (1.195 to 2.367) 0.035
Methotrexate use 0.736 (0.547 to 0.962) 0.024
*Analyses are adjusted for age and physical activity. DAS28, 28-joint disease
activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; RA, rheumatoid arthritis.
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Page 6 of 10healthy controls, irrespective of the criteria used. These
findings are in agreement with the results of earlier stu-
dies in both early RA [31] and long-standing RA
[28-35].
In the literature, prevalence of MetS varied consider-
ably, even using the same criteria; for example, using
the NCEP 2001, the prevalence ranged from 17% in
Mexican [30], 19% in South African [28], 19.9% in
Dutch [34], 38.3% in English [32], to 41.5% in Swedish
[33], 42% in American [31], and 44% in Greek [29]
patients with RA. Such diversity can be explained by dif-
ferences in the baseline characteristics and disease char-
acteristics [28-34]. We found that women with RA had
higher global estimated 10-year cardiovascular risk of
fatal CVD using the SCORE model (based on EULAR
guidelines) compared to healthy controls. These findings
are in line with the earlier studies [8,56]. The differences
between the rate of high risk CVD (SCORE above 10%)
and MetS in our study were also reported in the general
population using Framingham risk score [57]. The dis-
crepancy may be explained by the fact that many indivi-
duals with MetS have borderline elevations in risk
factors and thus may actually have either a low or inter-
mediate risk of CVD [58]. It is thus important to deter-
mine one’s 10-year cardiovascular risk in order to
decide whether or not to start treatment [5,8]. In RA,
treatment with statins and/or hypertensive agents should
be started when the SCORE is above 10%, provided
that the systolic BP is ≥140 mmHg and/or the LDL-C is
≥2.5 mmol/l [5]. It is noted that global risk scoring is
heavily dependent on age and, therefore, underestimates
risk of CVD in young individuals [57]. As MetS is not
likely to replace currently used global risk scoring algo-
rithms, both traditional risk factors and emerging meta-
bolic markers associated with MetS should be
incorporated in a future risk scoring system to be devel-
oped in order to adapt CVD risk prediction tools to the
epidemic of obesity [58]. We found that among indivi-
dual components of MetS, differences between women
with RA and controls were observed for hypertension,
low HDL-C levels, and abdominal obesity. These find-
ings are consistent with earlier studies in early RA [31].
The prevalence of hypertension varied from 51.7% to
73% in patients with RA [9]. A consistent pattern of
lower HDL-C levels is observed in patients with RA
compared with age- and sex-matched controls
[12,29,31,45,59] but there is conflict with regard to TC
and LDL-C levels. We found TC levels were similar
between the two groups while the atherogenic index
(TC/HDL-C ratio) and LDL-C levels were higher in
women with RA. These findings agree with an earlier
study [45], but disagree with others [12,31]. Again, such
discrepancy may be explained by differences in the base-
line characteristics and disease characteristics.
In this study, although the mean of BMI was similar
between the two groups, WC was higher in patients
with RA compared with healthy controls. These findings
agree with the results of earlier study in early RA [31].
The tendency towards abdominal obesity proves to be a
better predictor than BMI of cardiovascular risk in the
general population [21,24] and in RA [10,11]. The pro-
portion of underweight, in both groups, was lower but
overweight and obesity were higher than those in earlier
population-based study in Hanoi [60], suggesting that
although underweight remains the main concern, over-
weight and obesity make up an emerging burden in
Vietnam.
The association between ESR and DAS28 score with
t h ep r e s e n c eo ft h eM e t Si npatients with RA in our
study was also previously reported [29]. These findings
further support the role of chronic inflammation in
insulin resistance development [15]. Controlling sys-
temic inflammation using anti-tumour necrosis factor
(TNF) agents has been shown to lead to improvements
in insulin resistance in patients with RA [16]. A higher
HAQ score is likely to be associated with MetS in RA,
because patients with more severe disabling disease are
likely to lead a less active lifestyle, resulting in increased
obesity and alterations in the lipid profile [61].
In this study, less methorexate use was associated with
the presence of MetS in patients with RA. These find-
ings agree with some earlier studies [30,32], but disagree
with others [29,62]. These discrepancies may be
explained by differences in the baseline characteristics
and disease characteristics. Methotrexate use was asso-
ciated with a reduction in CVD-related mortality [63]
and improvements in lipid and glucose profiles, with
lower TG levels, higher HDL-C levels and lower plasma
glucose [32]. However, the mechanisms of action of
methorexate are not clearly determined; this may be
attributed to an anti-inflammatory effect [30] or a drug-
specific effect [32]. Further investigations are needed to
establish the effect of methotrexate on MetS.
No significant relationshipb e t w e e nt h ep r e s e n c eo f
MetS and glucocorticoids use in this study was also pre-
viously reported [31,32]. Glucocorticoid use is associated
with adverse lipid profiles in the general population, and
its long-term use is a risk factor for CVD [64]. However,
the relationship between glucocorticoid use and cardio-
vascular risk in patients with RA is complicated by the
fact that these drugs tend to be used more often in
patients with severe or intractable disease; therefore, it
is difficult to determine whether the disease or the treat-
ment increase the risk [64-66].
Prevalence of MetS in healthy controls was higher
than that in an earlier study in Vietnam [50]. Further-
more, we also found that the prevalence of MetS
increased with age in both groups as also reported in
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Page 7 of 10the earlier reports [31,32]. With the nation’s increasing
life expectancy, there will be a significant future increase
in the prevalence of MetS. Therefore, weight and MetS
control by association of dietary and physical activity
enhancement should be emphasized for the prevention
of obesity as well as the obesity-related CVD.
The results of this study must be interpreted within
the limitations of the methods used. The major limita-
tion was the small number of patients studied and that
they were exclusively women. In practice, there were
very few men with RA in our department, so we did not
include them in this study; consequently, we are not be
able to address the full scale problem of MetS in RA in
Vietnamese patients. Previous study in the general
population in Vietnam showed that men were more sus-
ceptible to Westernization through lifestyle modifica-
tions [21,50]. One study of 400 patients with RA
reported that the prevalence of MetS was similar in men
and women [32]; these findings differ from those
observed in the general population [21,23-27], where
age-matched men have been reported to have higher
rates of MetS. This discrepancy may be a consequence
of the ongoing inflammatory burden in the patients with
RA, altering some of the components of MetS [32].
Further studies with larger patient cohorts with both
men and women are useful. Also, we cannot exclude the
possibility of patient selection bias, because our hospital
is a tertiary referral centre. Another limitation was study
design being cross-sectional, so it was not possible to
make any cause-effect inference on the relationship
between RA characteristics and MetS. Prospective stu-
dies should prove valuable in determining these causal
relationships.
Conclusions
Women with early RA already had higher traditional
cardiovascular risk and prevalence of MetS compared
with healthy controls. A higher systemic inflammatory
marker, disease activity and disability scores, and less
methotrexate use were independent predictors asso-
ciated with the presence of MetS in women with early
RA. These findings suggest that clinicians should screen
for MetS in women with early RA to control its compo-
nents and, therefore, reduce their risk of cardiovascular
diseases.
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